|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,413,000 |
Market
Cap: |
9.16(B) |
Last
Volume: |
875,140 |
Avg
Vol: |
504,506 |
52
Week Range: |
$114.17 - $208.42 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,500 |
Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
40,296 |
45,669 |
50,307 |
151,828 |
Total Sell Value |
$7,357,263 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
Total People Sold |
2 |
4 |
5 |
6 |
Total Sell Transactions |
3 |
5 |
7 |
17 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Snodgres Jon |
Chief Financial Officer |
|
2020-02-26 |
4 |
S |
$86.11 |
$94,837 |
D/D |
(1,100) |
31,096 |
|
-34% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-02-26 |
4 |
S |
$86.60 |
$16,887 |
D/D |
(195) |
26,313 |
|
-34% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-02-26 |
4 |
S |
$86.10 |
$300,627 |
D/D |
(3,475) |
226,148 |
|
-34% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-02-25 |
4 |
OE |
$16.55 |
$549,190 |
D/D |
21,945 |
229,623 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-02-25 |
4 |
S |
$90.22 |
$1,074,447 |
D/D |
(11,735) |
219,413 |
|
-37% |
|
Cox John |
Director |
|
2020-02-24 |
4 |
S |
$92.76 |
$413,455 |
D/D |
(4,455) |
2,781 |
|
-37% |
|
Dawes Karen A |
Director |
|
2020-02-21 |
4 |
S |
$97.52 |
$394,793 |
D/D |
(4,000) |
113,034 |
|
-27% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2019-12-16 |
4 |
D |
$90.43 |
$26,677 |
D/D |
(295) |
26,508 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2019-12-05 |
4 |
OE |
$24.50 |
$99,980 |
D/D |
3,957 |
32,196 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2019-09-19 |
4 |
AS |
$81.82 |
$298,390 |
D/D |
(3,600) |
219,413 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2019-09-19 |
4 |
OE |
$16.55 |
$331,000 |
D/D |
20,000 |
223,013 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2019-09-09 |
4 |
AS |
$81.26 |
$996,521 |
D/D |
(12,094) |
203,013 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2019-07-15 |
4 |
D |
$85.95 |
$25,355 |
D/D |
(295) |
28,239 |
|
- |
|
Dawes Karen A |
Director |
|
2019-06-17 |
4 |
S |
$77.35 |
$100,168 |
D/D |
(1,295) |
117,034 |
|
- |
|
Dawes Karen A |
Director |
|
2019-06-17 |
4 |
OE |
$4.96 |
$99,200 |
D/D |
20,000 |
118,329 |
|
- |
|
Cooper Glenn L Md |
Director |
|
2019-05-23 |
4/A |
S |
$66.91 |
$334,715 |
D/D |
(5,000) |
59,709 |
|
- |
|
Cooper Glenn L Md |
Director |
|
2019-05-23 |
4/A |
OE |
$5.00 |
$120,000 |
D/D |
24,000 |
64,709 |
|
- |
|
Cooper Glenn L Md |
Director |
|
2019-05-23 |
4 |
S |
$66.91 |
$334,715 |
D/D |
(5,000) |
35,709 |
|
- |
|
Barthelemy Nicholas |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
5,109 |
|
- |
|
Cooper Glenn L Md |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
40,709 |
|
- |
|
Muir Glenn P |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
5,378 |
|
- |
|
Cox John |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,236 |
|
- |
|
Dawes Karen A |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,292 |
98,329 |
|
- |
|
Ryan Thomas F Jr |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
4,148 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2019-03-25 |
4 |
AS |
$58.45 |
$378,602 |
D/D |
(6,467) |
20,534 |
|
- |
|
647 Records found
|
|
Page 12 of 26 |
|
|